Data
They drew fifteen vials on Tuesday.
I sat in the chair and watched the tubes fill and thought about what I had written three weeks earlier: that I had been running my body on intermittent spot checks and narrative. That I did not have the controls in place to manage what I now understood to be an enterprise risk. I said I would do something about it. Fifteen vials of blood is doing something about it.
The first results arrived Wednesday. Not all at once. In waves. A few markers, then a cluster, then more the next morning. Some are still arriving. This is how monitoring begins: not with a clean summary, but with data coming in at the pace the system produces it.
I opened each batch the way I would open an audit report. Analytically. From the summary down.
The first thing I saw was the biological age estimate. The platform computes it from a composite of markers, weighted and modeled. Mine came back nearly eight years younger than my calendar age. It is a flattering number. It is the kind of number that makes you want to close the dashboard and feel good about yourself.
I did not close the dashboard.
The cholesterol picture confirmed what November suggested. The familial hypercholesterolemia is controlled. Not just managed; genuinely well controlled. I had one data point saying so. Now I have two. The inflammation marker was a surprise. Given the weight I am carrying, given the load I have written about across these posts, I expected that number to be elevated. It was nearly undetectable. I do not yet understand why, but I will take it.
Those are the findings that reassure.
There are others that do not.
The metabolic markers tell a different story than the headline. Some of the numbers I expected. Some I did not. The pattern they form, taken together, points to the kind of underlying dysfunction that does not announce itself in how you feel day to day but compounds quietly over time. Insulin response. Glucose regulation. The ratio between protective and harmful lipids. A hormonal picture that is not failing but is underperforming in ways that connect directly to energy, body composition, and metabolic resilience. Iron stores running low. An immune marker worth watching.
None of this is a diagnosis. I am not a clinician. But I can read a pattern. And the pattern is this: the systems that show up in a standard blood panel look fine. The systems underneath, the ones you only see when you measure broadly and look carefully, are strained.
In compliance terms: the surface-level controls are passing. The detailed audit found deficiencies.
This is exactly what Governance predicted. Not the specific findings, but the structure of them. A headline that flatters. Details that complicate. The distance between the two being the precise territory that requires corrective action.
I signed up for DEXA and resting metabolic rate testing this week. The first scans are Wednesday. Body composition. Metabolic baseline. More data. After that, when I have rebuilt enough aerobic base to make the results meaningful, a VO2 max test. That will be fall.
Blood panel. Body composition. Metabolic rate. Cardiopulmonary capacity. Four layers. Four baselines. A monitoring cadence, not a single event.
I have spent two months writing about systems I was not governing. The bike I was not riding. The body I was not measuring. The compliance architecture I was building at work while tolerating opacity at home. Each post moved closer to this: the moment where data replaces narrative.
The audit did not give me certainty. It gave me a baseline.
That is enough to begin.
Ken Wake is the author of Thinking Design (forthcoming) and a Professor and Entrepreneur in Residence at Georgetown University. His work explores systems, technology, design, and meaning. Tour de Ken is his weekly log.
